Skip to content
Screener

Regenxbio RGNX Short-Term Investments

Short-Term Investments at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.54B+1.2%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$217.34M-24.9%
Biogen logo
BiogenBIIB
$0
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$0-100%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$70.01M-62.1%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$167M-46.4%

Other financials

Income statement

See full
Revenue$108.0M+406%
Gross profit$14.9M+35.7%
Operating income$29.3M+146%
Net income$22.7M+132%
EPS (diluted)$0.43+131%

Balance sheet

See full
Cash & equivalents$36.5M-54.1%
Total debt$69.0M-11.3%
Total equity$71.8M-66.4%
Total assets$386.6M-33.5%

Cash flow

See full
Operating cash flow-$62.2M-26.1%
CapEx$760.0K+94.4%
Free cash flow-$63.0M-26.7%

Valuation

See full
Market cap$707.66M+87.8%
Enterprise value$740.13M+97.4%
P/S4.1×+1.6×

Profitability

See full
Gross margin59.7%+1.0pp
Operating margin-94.1%-9.3pp
Net margin-112.6%-0.1pp
FCF margin-143.1%-456pp

Returns & leverage

See full
Return on equity-137.6%-817pp
Debt / equity+0.6×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Regenxbio in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The source filing: Regenxbio’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336725
Line itemJune 30, 2026December 31, 2025
Assets
Current assets
Cash and cash equivalents$36,487$34,466
Marketable securities69,030195,604
Accounts receivable106,75426,379
Prepaid expenses11,90411,927
Restricted cash225
Other current assets11,75712,905

Item 1. Financial Statements.

FAQ

What is Regenxbio's short-term investments?
Regenxbio (RGNX) reported short-term investments of $69.03M in Q2 2026.
How has Regenxbio's short-term investments changed year-over-year?
Regenxbio's short-term investments decreased by 71.7% year-over-year, from $243.74M to $69.03M.
What is the long-term trend for Regenxbio's short-term investments?
Over 5 years (2020 to 2025), Regenxbio's short-term investments has grown at a 7.3% compound annual growth rate (CAGR), from $137.31M to $195.6M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.

Ask your AI about Regenxbio's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude